Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The effect of age on seropositivity is consistently reported both in the human population and in non-human primates [25, 26].”
From Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection (2024) · cites this paper as [25]
In the citing paper
“AAV is the most widely used vector for ocular gene therapy due to its non-pathogenic nature [42], transduction efficiency and ability to transduce a wide variety of cell types [43].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [42]
Citations
Cites
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Self-citationBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Self-citationJiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330
Davidoff, A. M., Gray, J. T., Ng, C. Y. C., Zhang, Y., Zhou, J., Spence, Y., Bakar, Y., & Nathwani, A. C. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.022 · Cited by 218
Wang, L., Calcedo, R., Bell, P., Lin, J., Grant, R. L., Siegel, D. L., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.031 · Cited by 212
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208 · cited 1×
“The discovery of new serotypes, including AAV8 (6), has provided alternative vectors with substantial advantages over AAV2 in terms of gene transfer efficiency (4, 11, 13, 18), lower prevalence of neutralizing antibodies (NAbs) in the human population (1, 3), and less propensity to activate T cells for capsid proteins…”
BackgroundSelf-citationTotal correction of hemophilia A mice with canine FVIII using an AAV 8 serotype
Sarkar, R., Tetreault, R., Gao, G., Wang, L., Bell, P., Chandler, R., Wilson, J. M., & Kazazian, H. H. (2004) · Blood · doi:10.1182/blood-2003-08-2954 · Cited by 201
Self-citationHurlbut, G. D., Ziegler, R. J., Nietupski, J. B., Foley, J. W., Woodworth, L. A., Meyers, E., Bercury, S. D., Pande, N. N., Souza, D. W., Bree, M. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.175 · Cited by 142
Efficacy of an Adeno-associated Virus 8-Pseudotyped Vector in Glycogen Storage Disease Type II
Sun, B., Zhang, H., Franco, L. M., Young, S. P., Schneider, A., Bird, A., Amalfitano, A., Chen, Y.-T., & Koeberl, D. D. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.10.004 · Cited by 140
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“…ubiquitinated once internalized in the cytosol, a step that is fundamental for targeting intracellular proteins for degradation through More than 50% of humans develop anti-AAV humoral immunity after the age of 3, 53,55 and thus exclusion of those with antibodies restricts the patient population.”
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Metadata
- Authors
- Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M.
- Affiliations
- University of Pennsylvania (US)
- Children's National (US)
- Corresponding author
- Wilson, James M.
- Venue
- Clinical and Vaccine Immunology
- Publisher
- American Society for Microbiology
- Published
- 2011-07-20
- Volume
- 18
- Issue
- 9
- Pages
- 1586-1588
- ISSN
- 1556-679X (ISSN-L)
- 1556-6811
- PMC
- PMC3165215
- OpenAlex
- W2149757665
- Cited by
- 345
- References
- 19
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 32 · 2023: 25 · 2022: 37 · 2021: 40 · 2020: 35 · 2019: 22 · 2018: 26 · 2017: 19 · 2016: 9 · 2015: 19 · 2014: 16 · 2013: 13 · 2012: 15
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Clinical and Vaccine Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (UL1RR031988)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30HD40677, P01HD057247, P30HD040677)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- adeno-associated virus, neutralizing antibodies, AAV serotype 2, AAV8, seroprevalence, antibody titers, natural infection, gene delivery vectors, neonates, children, adolescents
- MeSH terms
- Dependovirus, Adolescent, Antibodies, Viral, Child, Child, Preschool, Genetic Vectors, Humans, Infant, Newborn, Parvoviridae Infections, Serotyping, Transduction, Genetic, Genetic Therapy, Prevalence, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents. https://app.cochat.ai/papers/10.1128/cvi.05107-11
- The paper
- Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011). Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents. Clinical and Vaccine Immunology. https://doi.org/10.1128/cvi.05107-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.